#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Prophylaxis against transplant rejection Marfan's syndrome Anal cancer Infection in an immunocompromised host Rosai-Dorfman syndrome Pulmonary alveolar haemorrhage Acute promyelocytic leukaemia Neurofibromatosis Thrombotic thrombocytopenic purpura Spina bifida Hodgkin's disease Haemophilia B with anti factor IX Osteogenesis imperfecta Endometrial cancer IPEX syndrome More trials…

    Learn about Rare Diseases

    Osteosarcoma – Treatment Myxofibrosarcoma – Life with Disease Skin angiosarcoma – Trials in Disease Nephroblastoma – Treatment Antithrombin III deficiency – Life with Disease Nodal marginal zone B-cell lymphoma – Trials in Disease Glycogen storage disease type V Extranodal marginal zone B-cell lymphoma (MALT type) – Treatment Alveolar rhabdomyosarcoma Waldenstrom’s macroglobulinaemia refractory – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Dabigatran Etexilate Antipsychotics IHMA-2121771-1 Elenestinib Phosphate Nemtabrutinib Insulin Lispro Amisulpride Eltrombopag Selatogrel Xenon (129Xe) Pilocarpine Hydrochloride Valemetostat Tosilate Ngi226 Lavender Oil Farletuzumab Ecteribulin Apitegromab Levofloxacin Ketamine Hydrochloride Citric Acid Monohydrate Dexrazoxane Hydrochloride More therapies…

    Learn about Your Condition

    Ovarian cancer metastatic Neuromyopathy Angiopathy Hip arthroplasty Breast conserving surgery Asplenia Diminished ovarian reserve Hypotonia Dysmenorrhoea Pulmonary tuberculosis Mitral valve prolapse Oropharyngeal cancer Endometriosis Post procedural complication Neonatal asphyxia More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Skin and Connective Tissue Diseases

  • Study on Oxygen Therapy to Reduce Postoperative Complications in At-Risk Ankle Trauma Surgery Patients

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Oxygen
    France

  • Study of remibrutinib for long-term treatment of adult patients with chronic spontaneous urticaria who completed previous remibrutinib studies

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Remibrutinib
    Bulgaria Czechia Denmark France Germany Hungary +4

  • Study of amlitelimab injection compared to placebo for adults with severe alopecia areata (hair loss)

    Not recruiting

    2 1
    Investigated Diseases:
    • Alopecia areata
    Investigated Drugs:
    • Amlitelimab
    Bulgaria Czechia France Germany Italy The Netherlands +2

  • Study Comparing BP11 and Omalizumab for Patients with Chronic Spontaneous Urticaria Resistant to H1 Antihistamines

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Chronic spontaneous urticaria
    Investigated Drugs:
    • Omalizumab
    Bulgaria Hungary Latvia Lithuania Poland Slovakia

  • Study on Anifrolumab for Adults with Chronic or Subacute Cutaneous Lupus Erythematosus Unresponsive to Antimalarial Therapy

    Not recruiting

    3 1
    Investigated Drugs:
    • Anifrolumab
    Austria Bulgaria Denmark France Germany Greece +7

  • Study on the Long-Term Safety and Efficacy of Nemolizumab for Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Dermatitis atopic
    Investigated Drugs:
    • Nemolizumab
    Austria Belgium Bulgaria Czechia Estonia France +8
Previous Page
1 … 41 42 43 44 45 … 66
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!